biologics

Market Access
Card image cap

US frets over pharma supply chain security

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out.

R&D
Card image cap

Investing in biologics excellence

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs.